Clinical strategy is the set of decisions that connects what medicine knows to what your company builds, sells and delivers. For a healthtech or healthcare SaaS company, it answers which patients you serve, what care or workflow change you offer them, where it happens, who delivers it and what evidence proves it works. Companies that treat it as a document to write once tend to discover the gaps in front of buyers and investors. Companies that treat it as a leadership function, owned by someone with real clinical and business experience, find those gaps earlier. That is the work our Fractional Chief Medical Officer and advisory engagements are built around.
This guide is for founders, executives and investors with healthtech portfolio companies. It explains what clinical strategy is, what it has to specify, how to build a roadmap and how to measure whether it is working.
TL;DR
- Clinical strategy joins clinical knowledge, business principles and population health thinking so that patient outcomes and company outcomes improve together.
- A usable strategy states which patients, what intervention, where and how care is delivered, and who performs it.
- Build the roadmap in stages: define the clinical need, pick the pathway, plan evidence in steps, align product and care delivery, then set metrics and review cycles.
- Track three kinds of outcomes: patient engagement, clinical effectiveness and economic results for the enterprise customer.
- Physician leadership that speaks both clinical and business language is what turns the plan into buy-in and execution.
Table of Contents
- What clinical strategy means in healthcare
- What a clinical strategy has to decide
- Building a clinical strategy roadmap
- Where care delivery meets the roadmap
- Who needs to be in the room
- Measuring whether the strategy works
- What a clinical strategy looks like to an investor
- Work with a physician leader on your clinical strategy
- FAQ
- Sources
What clinical strategy means in healthcare
The term is used loosely, and the job listings that dominate search results for it do little to clarify it. A clearer definition comes from healthcare strategist Alex Tang, who in a 2024 AJHCS podcast interview describes clinical strategy as the intentional integration of clinical knowledge, business principles and population health management to drive both patient and organizational outcomes. He frames it as a bridge between medicine and management that leans toward business while relying on direct patient-care experience.
That definition matters for a startup because it rules out two common shortcuts. One is a purely commercial plan with a clinical slide added for credibility. The other is a purely clinical plan that ignores payment, workflow and adoption. A clinical strategy has to hold up in an exam room and in a boardroom.
How it differs from overall healthcare strategy
A healthcare organization's broader strategy covers markets, capital, partnerships, pricing and growth. Clinical strategy is the part that decides what care or clinical function the organization provides or enables, to whom, and with what proof. In a health system it shapes service lines. In a digital health company it shapes the product's clinical claims, the evidence plan, the workflows it changes and the clinical risks it must manage. The two must agree, but the clinical strategy is where the business model meets patient reality.
What a clinical strategy has to decide
A concise test comes from a cardiovascular service line article in Cardiac Interventions Today. It says a clinical strategy should specify which patients need treatment, what should be done for them, how and where care should be delivered (and where it should not), and who should perform it. The aim is reliable, high-value care.
Translated for a healthcare SaaS company, those four questions become:
- Which patients or populations? Define the clinical segment tightly: a condition, a risk tier, a care setting. "Adults with diabetes" is not a segment. "Adults with type 2 diabetes managed in primary care who are not meeting targets" is closer.
- What should be done for them? Name the intervention or workflow change your product enables, and the clinical standard it is measured against.
- How and where is it delivered? Inpatient, ambulatory, virtual or home. Just as important is where your product should not be used.
- Who performs it? Physicians, advanced practice providers, nurses, care coordinators, patients themselves. Every product shifts work between people, and that shift is where adoption succeeds or fails.
The UC Davis Health NEXT clinical strategic plan shows the same logic at health system scale. The five-year plan, developed with faculty and staff input, centers on the patient and equity. It includes building a regional system of care, improving patient and care-team experience, advancing health equity and growing patient-centric service lines organized around populations or disease states across inpatient, ambulatory, digital and home settings. If you sell to systems like this one, your product has to fit into a plan like this, and your own clinical strategy should be written so a buyer can see where.
Building a clinical strategy roadmap
A roadmap turns the four questions into sequenced work. This is the order we recommend for an early or growth-stage healthtech company.

Step 1: Define the clinical need and the gap
Start with where current care falls short. Dan Gebremedhin, MD, of Flare Capital Partners points to studies from Finn Ventures and Rock Health/JMIR showing that a majority of digital health ventures lack strong clinical robustness. His advice is to understand evidence-based practices and established outcome metrics first, so you can see where existing care falls short before applying a digitally enabled clinical model.
Where it goes wrong: founders start from the technology and look for a clinical problem afterward. A clinician reviewing your thesis early catches this when it is cheap to fix.
Step 2: Choose a realistic clinical pathway
A VentureWell clinical strategy case by Lyn Denend argues that an effective strategy defines a pathway that addresses top priorities realistically. It favors a progressive series of studies with expanding indications over one ambitious single-indication trial. The example is the implantable cardioverter-defibrillator, first approved for secondary prevention after cardiac arrest, with use extended to primary prevention after the MADIT trial.
The lesson applies beyond devices. Software that touches clinical decisions should begin with the narrowest claim you can prove, then widen. A narrow, credible first indication is easier to sell and easier to defend than a broad claim you cannot yet support.
Step 3: Plan evidence as a series of value-building steps
Denend also stresses that testing should be built into the development plan as a series of value-building steps, so the technology ends up addressing a clear clinical need and meeting regulatory, reimbursement and market requirements. Do not treat evidence as something that happens after the product is finished.
For digital health specifically, the Digital Medicine Society's evidence resource tells companies to build a cohesive evidence strategy that integrates clinical, real-world, economic and patient-centric data. It describes an "evidence funnel" that refines priorities against regulatory, payor, provider and patient needs. Further steps include assessing opportunity cost against usual care, defining data requirements, drafting hypotheses, seeking joint scientific advice from regulators and payors, and then testing, implementing and optimizing.
For a founder's view of the same discipline, see our guide to clinical evidence building best practices.
Step 4: Align the evidence design with how the product actually works
A 2024 viewpoint by Bolinger and Tyl argues that digital health solutions often fail to show clinical results because study designs overlook key traits: implementation at the system and patient level, complexity, multiple indirect outcomes, variable mechanisms of action and short development cycles. They recommend mapping the mechanism of action, using usual-care controls, considering alternative randomization and drawing on real-world data and platform research.
Their first step is the one most teams skip. Define the mechanism of action and context of use by mapping the behavior changes required from patients and combining patient journeys, user journeys and clinician protocols. Only then choose the scientific approach. A product that depends on clinicians changing a habit cannot be evaluated like a drug.
Step 5: Connect the strategy to the payer and regulatory environment
Evidence standards are rising. The Institute for Clinical and Economic Review and the Peterson Health Technology Institute published a 2023 value assessment framework for digital health technologies. It sets evidence standards to guide developers and to help organizations adopt technologies with the strongest evidence of better outcomes and cost savings. It is intended as the basis for their future evaluations. If your buyers read evaluations like these, your roadmap should anticipate them.
Regulatory questions belong here too: whether your software functions as a regulated device, what claims you can make and what clinical validation your pathway needs. These are decisions to make early, with someone who has worked through them, because they shape product scope and sales messaging.
Step 6: Prioritize and sequence
A November 2024 commentary by Huberty and Beatty advises digital health companies to prioritize scientific initiatives by impact, required resources and alignment with business goals. They suggest starting with low-cost wins such as retrospective analyses and cross-sectional surveys, and tracking success metrics tied to business objectives to justify resource allocation. A good roadmap shows what you will learn in the next quarter, the next year and the next two years, and what each result unlocks commercially.
Where care delivery meets the roadmap
Strategy fails most often at delivery. A plan that names the right patients and the right intervention still collapses if workflows, documentation and staffing do not support it. Providers that scale a service line need operations built for consistent care, including licensing, accreditation readiness and documentation that supports the clinical model. Specialists in operations and systems design for regulated providers work on exactly this layer. For a healthtech company, the parallel is clinical operations: the people, processes and safety oversight that make your clinical claims true in a live customer site. Our founder's guide to clinical operations for a healthtech startup covers that side in more depth.
Who needs to be in the room
A clinical strategy written by the commercial team alone will miss clinical risk. One written by clinicians alone will miss the market. Huberty and Beatty contend that strong scientific leadership, championing integration through clear communication, strategic prioritization and cultural buy-in, is essential if digital health companies are to turn science into product innovation, credibility and competitive advantage.
Tang makes a similar point from the health system side. He argues that clinical strategists break down silos between business and clinical staff, spot operational risks and clinical blind spots before they affect outcomes, and speed up change management by speaking both languages. That creates buy-in from front-line staff, not just senior leadership.
In practice, a healthcare SaaS company needs four contributors:
- A physician leader who owns clinical safety, credibility and the evidence agenda.
- Product and engineering who translate clinical requirements into workflow.
- Commercial leadership who test the strategy against buyer needs and reimbursement.
- Front-line clinical users whose actual workflow the product must fit.
Most seed and Series A companies cannot justify a full-time Chief Medical Officer. That is the gap a fractional CMO is built to close.
Measuring whether the strategy works
A strategy you cannot measure is a set of opinions. Flare Capital Partners names three outcomes to monitor: patient engagement and activation, clinical effectiveness, and economic outcomes for enterprise stakeholders. The same piece notes that HEDIS is used by over 90% of US health plans and that CMS Star Ratings metrics are publicly accessible, which gives you established measures to align with rather than inventing your own.
The Medical Affairs Professional Society offers a useful standard for the objectives behind the metrics. Its 2023 guidance on strategic objectives says medical objectives should align with product vision, be clear and specific, be measurable with trackable metrics, be feasible and be consistent with the overall strategy. Metrics should establish baselines, use a common collection tool, mix quantitative and qualitative measures and cover short- and long-term impact.
Its 2025 guidance on value and impact recommends an Establish, Analyze, Adjust cycle. You establish measurements aligned to the strategic plan, analyze impact against each milestone and decide what to adjust. Regular review keeps the plan relevant, and cross-functional alignment keeps execution coordinated.
A simple scorecard for a healthtech company might look like this:
| Outcome area | Example question | How to use it |
|---|---|---|
| Patient engagement and activation | Do patients use the product as intended, and keep using it? | Baseline at launch, review monthly |
| Clinical effectiveness | Does the target measure improve against usual care? | Tie to the evidence plan milestones |
| Economic outcomes | Does the customer see cost or revenue impact? | Report in the buyer's own terms |
For a deeper look at choosing the few metrics that matter, read our piece on clinical outcomes metrics for health systems and SaaS.
What a clinical strategy looks like to an investor

Investors and board members read a clinical strategy for three signals. First, whether the clinical problem is real and sized. Second, whether the evidence plan is staged and affordable. Third, whether a credible clinical leader stands behind it. Weakness in any of the three shows up in diligence, and in customer security and clinical review committees. For portfolio companies, a periodic clinical strategy review is a practical way to find which companies have a defensible clinical story and which need medical leadership added.
For a fuller walk-through aimed at founders, see our clinical strategy guide for digital health companies.
Our perspective
Most clinical strategy problems we see described in healthtech are not strategy problems at heart. They are translation problems. The product team talks in features, the clinicians talk in patients and risk, and the investors talk in milestones. Nobody owns the sentence that connects all three.
We believe that sentence has to come from someone who has cared for patients and has also worked on the business side. That is the dual perspective Paul Bergeron brings: more than 25 years across medicine and business. It is why our advisory and Fractional Chief Medical Officer work covers clinical strategy development, product evaluation, regulatory guidance, clinical operations, market readiness and investor support under one roof.
Our view is simple. Start with the narrowest clinical claim you can defend. Build evidence in steps. Put a physician leader in the room before the first customer asks for one. A clinical strategy earns its value when a front-line clinician, a buyer and an investor each read it and conclude the company understands their problem.
Paul Bergeron MD, MBA
Work with a physician leader on your clinical strategy
The StartUp MD is a healthcare advisory firm for healthcare SaaS and healthtech companies, led by Paul Bergeron, MD, MBA. We offer Fractional Chief Medical Officer leadership on a retainer basis and project-based advisory services, including clinical strategy development, product evaluation, regulatory guidance, market readiness assessment and investor support. Clients get direct access to an advisor with both clinical and business expertise. Explore the Fractional CMO and advisory services to see which fits your stage.

Investors with portfolio companies can use the same engagements to review a company's clinical strategy before a raise or a major customer launch. You can also start at The StartUp MD.
FAQ
What is clinical strategy in healthcare?
It is the deliberate integration of clinical knowledge, business principles and population health thinking to improve patient and organizational outcomes. In practice it decides which patients are served, what care is delivered, where and by whom, and what evidence supports it.
What should a clinical strategy roadmap include?
A roadmap should include the defined clinical need, the target population, the intervention or workflow change, the evidence plan in staged steps, regulatory and payer considerations, and the metrics and review cycle. Each stage should state what it unlocks commercially, so the plan can be funded in order of impact.
Who should own clinical strategy at a healthtech startup?
A physician leader with business experience should own it, working closely with product, commercial and front-line clinical users. Many early-stage companies do not need a full-time Chief Medical Officer yet, which is where fractional medical leadership fits.
How do you know whether a clinical strategy is working?
Track patient engagement and activation, clinical effectiveness and economic outcomes for your enterprise customers. Set baselines up front, tie each metric to a milestone and review on a regular cycle so you can adjust.
Sources
- Clinical Strategy: Alex Tang on Healthcare Innovation (AJHCS)
- The High-Performing Cardiovascular Service Line (Cardiac Interventions Today)
- UC Davis Health NEXT Clinical Strategic Plan
- Clinical Strategy case (VentureWell)
- DiMe Resource: IEP Stage B
- Key Considerations for Designing Clinical Studies to Evaluate Digital Health (PMC)
- ICER and PHTI value assessment framework for digital health technologies (PMC)
- Integrating science into digital health workflows (PMC)
- Surviving Digital Health: Achieving Key Outcomes (Flare Capital Partners)
- Crafting strategic objectives to guide and measure success (MAPS)
- Measuring Value and Impact in Medical Affairs (MAPS)
